CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
warfarindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000614
NCT00000614Phase 3Completed
CompareCT.gov

Prevention of Recurrent Venous Thromboembolism (PREVENT)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Mar 16, 2016

In Brief

A Phase 3 clinical trial evaluating warfarin for Cardiovascular Diseases and 5 related conditions. Completed.

Detailed Summary

A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Heart Diseases, Peripheral Vascular Diseases, Thromboembolism, Vascular Diseases, Venous Thromboembolism
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1998
Study CompletionAug 1, 2004
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

warfarindrug